Stay updated on SAR442720 Combo Study in Advanced Malignancies Clinical Trial
Sign up to get notified when there's something new on the SAR442720 Combo Study in Advanced Malignancies Clinical Trial page.

Latest updates to the SAR442720 Combo Study in Advanced Malignancies Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check15 days agoChange DetectedThe web page has been updated to reflect the completion of a clinical study evaluating SAR442720 in combination with pembrolizumab, including detailed results and participant data. Key changes include the addition of results posted on April 20, 2025, and the clarification of study details across multiple parts, including participant dosing and study duration.SummaryDifference100%
- Check22 days agoChange DetectedThe webpage has undergone significant changes, including the removal of detailed primary and secondary objectives related to the study of SAR442720 in combination with pembrolizumab and adagrasib, while adding new identifiers and collaborators.SummaryDifference29%
- Check30 days agoChange DetectedThe page has been updated to reflect that results have been submitted, and the version has been upgraded from v2.14.3 to v2.14.4.SummaryDifference0.2%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
Stay in the know with updates to SAR442720 Combo Study in Advanced Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SAR442720 Combo Study in Advanced Malignancies Clinical Trial page.